Amgen's erenumab meets Phase III migraine endpoint

Amgen Inc. (NASDAQ:AMGN) said erenumab ( AMG 334) met the primary endpoint in the Phase III ARISE trial to prevent episodic migraine. From baseline to 12 weeks, a 70 mg dose of the compound significantly reduced monthly migraine days by 2.9 vs. 1.8 for placebo.

Erenumab is a human mAb inhibiting the receptor for calcitonin gene-related peptide ( CGRP). The ARISE data are the first Phase III results for a mAb targeting the peptide or its receptor. This year, Amgen expects to complete another Phase III study, STRIVE, evaluating 70 mg and 140 mg erenumab in episodic migraine patients. ...